Answers are grounded in this paper and cite their sources.
At the 5th FDA-Drug Industry Association (DIA) Workshop on 'Pharmacogenomics in Drug Development and Regulatory Decision Making', track four focused on the current thinking and issues in the co-development of therapeutic drugs or biologics, and their companion diagnostic products. Identification and validation of genomic and other biomarkers are becoming important components of drug-development strategies, and recent successes show the power of personalized approaches to change the benefit-risk paradigm for new drugs.
No takes yet. Share an insight, caveat, or question.
Hinman et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: